Amyotrophic lateral sclerosis (ALS) is a severe disease that causes thousands of deaths annually. Current treatments are either limited in effectiveness or not broadly applicable. To discover new options, we conducted a genetics-based screen to identify drugs that could be repurposed for ALS. We analyzed genome-wid...
S. Saez-Atienzar, Luis A. Rojas-Colón, Ruth Chia et al.· npj Digital Medicine· 0 citations
Abstract Molecular connectivity analysis with positron emission tomography (PET) imaging offers a promising approach for characterising brain network alterations in neurodegenerative disorders. In this study, we introduce Wasserstein distance (WD) as an alternative to Kullback–Leibler divergence similarity estimation (...
Chun-Meng Tang, Joke de Vocht, P. van Damme et al.· Imaging neuroscience· 0 citations
Cognitive and behavioral dysfunction in frontotemporal dementia (FTD) evolves along a clinical continuum from a clinically silent stage of disease, through a prodromal period, often referred to as mild cognitive impairment (MCI) and/or mild behavioral impairment (MBI), and into a clinically manifest stage recognized by...
M. Benatar, E. Huey, Chiadikaobi Onyike et al.· Brain : a journal of neurolo...· 1 citation
An international workshop was convened in London, Canada in 2025 to review the evidence for existing or evolving biomarkers suitable for the detection of either ALS or FTD pathobiology prior to phenoconversion and/or predict phenoconversion in at risk individuals.
Michael J. Strong, Neil S. Donison, A. Al-Chalabi et al.· Brain : a journal of neurolo...· 0 citations
A new model is developed that is validated across diverse ALS populations, can handle discrepancies between genotyping technologies, and is applicable to individual external samples, and has the potential to extend genetic risk assessment to all individuals, regardless of their family history or the presence of known A...
Jia-Jing Hu, Oliver Pain, A. Al Khleifat et al.· Genome Medicine· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
